2. Search Result
Search Result
Results for "

L-2-Aminopropionic acid-1-<sup>13</sup>C

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

6

Peptides

17

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0229S2
    L-Alanine-15N

    L-2-Aminopropionic acid-<sup>15sup>N

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 15N is the 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system .
    L-Alanine-15N
  • HY-N0229S6
    L-Alanine-3-13C

    L-2-Aminopropionic acid-3-<sup>13sup>C

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine-3- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-3-13C
  • HY-N2362S
    DL-Alanine-13C-1

    DL-2-Aminopropionic acid-<sup>13sup>C-1

    		 Endogenous Metabolite Metabolic Disease
    DL-Alanine- 13C-1 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
    DL-Alanine-13C-1
  • HY-N0229S1
    L-Alanine-1-13C

    L-2-Aminopropionic acid-1-<sup>13sup>C

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine-1- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-1-13C
  • HY-N2362S1
    DL-Alanine-13C-3

    DL-2-Aminopropionic acid-<sup>13sup>C-3

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    DL-Alanine- 13C-3 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
    DL-Alanine-13C-3
  • HY-N0229S11
    L-Alanine-1-13C,15N

    L-2-Aminopropionic acid-1-<sup>13sup>C,<sup>15sup>N

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine-1- 13C, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-1-13C,15N
  • HY-N0229S9
    L-Alanine-13C2

    L-2-Aminopropionic acid-<sup>13sup>C2

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 13C2 is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-13C2
  • HY-N2362S5
    DL-Alanine-15N

    DL-2-Aminopropionic acid-<sup>15sup>N

    		 Endogenous Metabolite Metabolic Disease
    DL-Alanine- 15N is the 15N labeled DL-Alanine . DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
    DL-Alanine-15N
  • HY-N0229S7
    L-Alanine-2-13C

    L-2-Aminopropionic acid-2-<sup>13sup>C

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine-2- 13C is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-2-13C
  • HY-N0229S
    L-Alanine-2-13C,15N

    L-2-Aminopropionic acid-2-<sup>13sup>C,<sup>15sup>N

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine-2- 13C, 15Nis the 13C-labeled and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-2-13C,15N
  • HY-N0229S8
    L-Alanine-13C3

    L-2-Aminopropionic acid-<sup>13sup>C3

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 13C3 is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-13C3
  • HY-N0229S15
    L-Alanine-13C2,15N

    L-2-Aminopropionic acid-<sup>13sup>C2,<sup>15sup>N

    		 Endogenous Metabolite Metabolic Disease
    L-Alanine- 13C2, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-13C2,15N
  • HY-N0229S10
    L-Alanine-13C3,15N

    L-2-Aminopropionic acid-<sup>13sup>C3,<sup>15sup>N

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 13C3, 15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-13C3,15N
  • HY-N0229S4
    L-Alanine-13C,d1

    L-2-Aminopropionic acid-<sup>13sup>C,d1

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 13C,d is the 13C- and deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-13C,d1
  • HY-N0229S14
    L-Alanine-15N,d4

    L-2-Aminopropionic acid-<sup>15sup>N,d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 15N,d4 is the deuterium and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-15N,d4
  • HY-N2362S9
    DL-Alanine-13C2,15N

    DL-2-Aminopropionic acid-<sup>13sup>C2,<sup>15sup>N2

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    DL-Alanine- 13C2, 15N (DL-2-Aminopropionic acid- 13C2, 15N) is 13C and 15N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
    DL-Alanine-13C2,15N
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-N0229S5
    L-Alanine-13C3,15N,d4

    L-2-Aminopropionic acid-<sup>13sup>C3,<sup>15sup>N,d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Metabolic Disease
    L-Alanine- 13C3, 15N,d4 is the deuterium, 13C-, and 15-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-13C3,15N,d4
  • HY-P2595
    SKF 103784

    		Endogenous Metabolite Cardiovascular Disease
    SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
    SKF 103784
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P1162
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

    SKF 100273

    		 Vasopressin Receptor Metabolic Disease
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: